Aurora Cannabis (TSE:ACB) Stock Rating Upgraded by Atb Cap Markets

Atb Cap Markets upgraded shares of Aurora Cannabis (TSE:ACB) from a hold rating to a strong-buy rating in a research note released on Wednesday,Zacks.com reports.

Several other brokerages have also weighed in on ACB. TD Securities upgraded Aurora Cannabis to a “strong-buy” rating in a research note on Thursday, December 12th. ATB Capital reduced their target price on Aurora Cannabis from C$11.00 to C$8.50 in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of C$5.85.

Aurora Cannabis Stock Down 3.7 %

TSE:ACB opened at C$8.63 on Wednesday. The company’s fifty day moving average price is C$6.08 and its 200-day moving average price is C$7.18. The firm has a market capitalization of C$471.72 million, a P/E ratio of -13.70 and a beta of 2.71. The company has a debt-to-equity ratio of 16.95, a current ratio of 3.76 and a quick ratio of 2.48. Aurora Cannabis has a 1-year low of C$3.84 and a 1-year high of C$12.85.

Aurora Cannabis (TSE:ACB) last posted its earnings results on Wednesday, November 6th. The company reported C$0.05 earnings per share for the quarter, beating the consensus estimate of C($0.30) by C$0.35. Aurora Cannabis had a negative net margin of 11.53% and a negative return on equity of 6.13%. During the same quarter last year, the business posted ($0.70) earnings per share. As a group, equities research analysts anticipate that Aurora Cannabis will post -0.22 EPS for the current year.

Aurora Cannabis Company Profile

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.